(Q33409083)

26 July 2017

title

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer (English)

1 reference

26 July 2017

1 reference

2

Thomas Bachelot

1 reference

26 July 2017

Véronique Diéras

1

1 reference

26 July 2017

publication date

14 July 2013

1 reference

26 July 2017

1 reference

26 July 2017

volume

9

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

111-122

1 reference

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Semisynthetic maytansine analogues for the targeted treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Drug-conjugated monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Cell killing by antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

The cardiac safety of trastuzumab in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0287-4

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

21 January 2018

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

A therapeutic trial of maytansine

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

12 December 2020

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

1 reference

12 December 2020

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

1 reference

12 December 2020

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

1 reference

12 December 2020

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

1 reference

12 December 2020

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

12 December 2020

10.1007/S11523-013-0287-4

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1036245819

0 references

1 reference